PRODUCT INFORMATION

HM61713

Item No. 19481

CAS Registry No.: 1353550-13-6
Formal Name: N-[3-[[2-[[4-(4-methyl-1-piperazinyl) phenyl]amino]thieno[3,2-d]pyrimidin-4-yl] oxy]phenyl]-2-propenamide
Synonyms: BI-1482694, Olmutinib
MF: $C_{26}H_{26}N_6O_2S$
FW: 486.6
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

HM61713 is supplied as a crystalline solid. A stock solution may be made by dissolving the HM61713 in the solvent of choice, which should be purged with an inert gas. HM61713 is soluble in the organic solvent DMSO at a concentration of approximately 44 mg/ml.

Description

HM61713 is an inhibitor of mutant EGFR (IC_{50} = 0.01 µM for $EGFRT^{790M/L858R}$).[1] It is selective for $EGFR^{790M/L858R}$ over PI3Kα (IC_{50} = >10 µM). HM61713 is cytotoxic to A549, H1975, and H460 lung and MCF-7 breast cancer cells (IC_{50}s = 4.29, 0.52, 5.29, and 26.9 µM, respectively). It reduces tumor growth in an ETS1-overexpressing doxorubicin-resistant K562 leukemia mouse xenograft model when administered at a dose of 30 mg/kg in combination with doxorubicin.[2]

References

1. Hu, X., Tang, S., Yang, F., *et al.* Design, synthesis, and antitumor activity of olmutinib derivatives containing acrylamide moiety. *Molecules* **26(10)**, 3041 (2021).
2. Zhong, J., Zhang, J., Yu, X., *et al.* Olmutinib reverses doxorubicin resistance in ETS1-overexpressing leukemia cells. *Med. Sci. Monit.* **26**, e924922 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM